1. |
Kelly CP, La Mont JT. Clostridium difficile-more difficult than eve. N Engl J Med, 2008, 359(18):1932-1940.
|
2. |
McDonald EG, Milligan J, Frenette C, et al. Contiunous proton pump inhibitor therapy and the associated risk of recurrent clostridium difficile infection. JAMA Intern Med, 2015, 175(5):784-791.
|
3. |
Zilberberg MD, Reske K, Olsen M, et al. Risk factors for recurrent clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode:a retrospective cohort study. BMC Infect Dis, 2014(14):306-312.
|
4. |
Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe:a hospital-based survey. Lancet, 2011, 377(9759):63-73.
|
5. |
Wells GA, Shea B, O'Connell D, et al. Th e Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at:http://www.ohri.ca/programs/clinicalepidemiology/oxford.htm.
|
6. |
Yuhara H, Steinmaus C, Cohen SE, et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol, 2011, 106(11):1911-1921.
|
7. |
Dial S. Risk of clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors:cohort and case-control studies. CMAJ, 2004, 171(1):33-38.
|
8. |
Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial clostridium difficile infection. Arch Intern Med, 2010, 170(9):784-790.
|
9. |
Dalton BR, Lye-Maccannell T, Henderson EA, et al. Proton pump inhibitors increase significantly the risk of clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther, 2009, 29(6):626-634.
|
10. |
Shah S, Lewis A, Leopold D, et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM, 2000, 93(4):175-181.
|
11. |
Yip C, Loeb M, Salama S, et al. Quinolone use as a risk factor for nosocomial clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol, 2001, 22(3):572-575.
|
12. |
Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for clostridium difficile diarrhoea. J Hosp Infect, 2003, 54(3):243-245.
|
13. |
Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired clostridium difficile-associated disease. JAMA, 2005, 294(3):2989-2995.
|
14. |
Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med, 2005, 353(8):2442-2449.
|
15. |
Modena S, Bearelly D, Swartz K, et al. Clostridium difficile among hospitalized patients receiving antibiotics:a case-control study. Infect Control Hosp Epidemiol, 2005, 26(3):685-690.
|
16. |
Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol, 2005, 26(3):273-280.
|
17. |
Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of clostridium difficile. Arch Intern Med, 2006, 166(7):2518-2524.
|
18. |
Lowe DO, Mamdani MM, Kopp A, et al. Proton pump inhibitors and hospitalization for clostridium difficile-associated disease:a population-based study. Clin Infect Dis, 2006, 43(4):1272-1276.
|
19. |
Yearsley KA, Gilby LJ, Ramadas AV, et al. Proton pump inhibitor therapy is a risk factor for clostridium difficile-associated diarrhea. Aliment Pharmacol Ther, 2006, 24(4):613-619.
|
20. |
Akhtar AJ, Shaheen M. Increasing incidence of clostridium difficile-associated diarrhea in African-American and Hispanic patients:association with the use of proton pump inhibitor therapy. J Natl Med Assoc, 2007, 99(4):500-504.
|
21. |
Cadle RM, Mansouri MD, Logan N, et al. Association of proton-pump inhibitors with outcomes in clostridium difficile colitis. Am J Health Syst Pharm, 2007, 64(22):2359-2363.
|
22. |
Dubberke ER, Reske KA, Yan Y, et al. Clostridium difficile——associated disease in a setting of endemicity:identification of novel risk factors. Clin Infect Dis, 2007, 45(12):1543-1549.
|
23. |
Jayatilaka S, Shakov R, Eddi R, et al. Clostridium difficile infection in an urban medical center:five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci, 2007, 37(6):241-247.
|
24. |
Mcfarland LV, Clarridge JE, Beneda HW, et al. Fluoroquinolone use and risk factors for clostridium difficile-associated disease within a Veterans Administration Health Care System. Clin Infect Dis, 2007, 45(9):1141-1151.
|
25. |
Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol, 2008, 103(9):2308-2313.
|
26. |
Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol, 2008, 29(7):44-50.
|
27. |
Kim JW. Proton pump inhibitors as a risk factor for recurrence of clostridium-difficile-associated diarrhea. World J Gastroenterol, 2010, 16(28):3573-3577.
|
28. |
Kim YG, Jang BI, Choi EJ, et al. Proton pump inhibitors with recurrent clostridium difficile associated disease:a case-control analysis matched by propensity score. J Clin Gastroenterology, 2012, 46(5):397-400.
|
29. |
Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent clostridium difficile infection. Arch Intern Med, 2010, 170(9):772-778.
|
30. |
Linney S, Fernandes T, Einarson T, et al. Association between use of proton pump inhibitors and a clostridium difficile-associated disease outbreak:case-control study. Can J Hosp Pharm, 2010, 63(1):31-37.
|
31. |
Dial S. Proton pump inhibitor use and risk of community-acquired clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ, 2006, 175(7):745-748.
|
32. |
Kutty PK, Woods CW, Sena AC, et al. Risk factors for and estimated incidence of community-associated clostridium difficile infection, North Carolina, USA. Emerg Infect Dis, 2010, 16(2):197-204.
|
33. |
Marwick CA, Yu N, Lockhart MC, et al. Community-associated clostridium difficile infection among older people in Tayside, Scotland, is associated with antibiotic exposure and care home residence:cohort study with nested case-control. J Antimicrob Chemother, 2013, 68(12):2927-2933.
|
34. |
Novack L, Kogan S, Gimpelevich L, et al. Acid suppression therapy does not predispose to clostridium difficile infection:the case of the potential bias. PLoS One, 2014, 9(10):e110790.
|
35. |
Mori N, Aoki Y. Clinical characteristics and risk factors for community-acquired clostridium difficile infection:A retrospective, case-control study in a tertiary care hospital in Japan. J Infect Chemother, 2015, 21(12):864-867.
|
36. |
Barletta JF, El-Ibiary SY, Davis LE, et al. Proton pump inhibitors and the risk for hospital-acquired clostridium difficile infection. Mayo Clin Proc, 2013, 88(10):1085-1090.
|
37. |
Bishara J, Farah R, Mograbi J, et al. Obesity as a risk factor for clostridium difficile Infection. Clin Infect Dis, 2013, 57(4):489-493.
|
38. |
Pakyz AL, Jawahar R, Wang Q, et al. Medication risk factors associated with health care-associated clostridium difficile infection:a multilevel model case-control study among 64 US academic medical centres. J Antimicrob Chemother, 2014, 69(4):1127-1131.
|
39. |
Soes LM, Holt HM, Böttiger B, et al. Risk factors for clostridium difficile infection in the community:a case-control study in patients in general practice, Denmark, 2009-2011. Epidemiol Infect, 2014, 142(07):1437-1448.
|
40. |
Barletta JF, Sclar DA. Proton pump inhibitors increase the risk for hospital-acquired clostridium difficile infection in critically ill patients. Crit Care Med, 2014, 18(6):714-717.
|
41. |
Sahay T, Ananthakrishnan AN. Vitamin D deficiency is associated with community-acquired clostridium difficile infection:a case-control study. BMC Infect Dis, 2014, 14(2):661-666.
|
42. |
Aldrete SDM, Magee MJ, Friedman-Moraco RJ, et al. Characteristics and antibiotic use associated with Short-Term risk of clostridium difficile infection among hospitalized patients. AJCP, 2015, 143(6):895-900.
|
43. |
Stevens V, Dumyati G, Brown J, et al. Differential risk of clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidem Dr S, 2011, 20(10):1035-1042.
|
44. |
Lin YC, Huang YT, Lee TF, et al. Characteristics of patients with clostridium difficile infection in Taiwan. Epidemiol Infect, 2013, 141(10):2031-2038.
|
45. |
Wang Y, Atreja A, Wu X, et al. Similar outcomes of IBD inpatients with clostridium difficile Infection detected by ELISA or PCR assay. Dig Dis Sci, 2013, 58(8):2308-2313.
|
46. |
Brown KA, Fisman DN, Moineddin R, et al. The magnitude and duration of clostridium difficile infection risk associated with antibiotic therapy:a hospital cohort study. PLoS One, 2014, 9(8):e105454.
|
47. |
Kaneko T, Matsuda R, Taguri M, et al. Clostridium difficile infection in patients with ulcerative colitis:Investigations of risk factors and efficacy of antibiotics for steroid refractory patients. Clin Res Hepatol Gastroenterol, 2011, 35(4):315-320.
|
48. |
Ananthakrishnan AN, Cagan A, Gainer VS, et al. Higher plasma vitamin D is associated with reduced risk of clostridium difficile infection in patients with inflammatory bowel diseases. Aliment Pharmacol Ther, 2014, 39(10):1136-1142.
|
49. |
Regnault H, Bourrier A, Lalande V, et al. Prevalence and risk factors of clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease:A retrospective assessment. Dig Liver Dis, 2014, 46(12):1086-1092.
|
50. |
Ticinesi A, Nouvenne A, Folesani G, et al. Multimorbidity in elderly hospitalised patients and risk of clostridium difficile infection:a retrospective study with the Cumulative Illness Rating Scale (CIRS). BMJ, 2015, 5(10):9316-9322.
|
51. |
Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, et al. Risk factors associated with clostridium difficile infection in adult oncology patients. Support Care Cancer, 2015, 23(6):1569-1577.
|
52. |
Lee S. Ertapenem prophylaxis associated with an increased risk of clostridium difficile infection among surgical patients infect. Control Hos Epidemiol, 2015; 36(11):1351-1354.
|
53. |
Leonard AD, Ho KM, Flexman J. Proton pump inhibitors and diarrhea related to clostridium difficile infection in hospitalised patients:a case-control study. Intern Med J, 2012, 42(5):591-594.
|
54. |
George RH, Symonds JM, Dimock F, et al. Identification of clostridium difficile as a cause of pseudomembranous colitis. BMJ, 1978, 1(3):695-698.
|
55. |
Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol, 2001, 15(3):511-517.
|
56. |
Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med, 2000, 342(6):390-400.
|
57. |
Drug Safety and Availability. FDA Drug Safety Communication:Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Avaliable at:http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm.
|